0000899243-20-021598.txt : 20200806
0000899243-20-021598.hdr.sgml : 20200806
20200806060949
ACCESSION NUMBER: 0000899243-20-021598
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200803
FILED AS OF DATE: 20200806
DATE AS OF CHANGE: 20200806
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Leen Ann M.
CENTRAL INDEX KEY: 0001763026
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39409
FILM NUMBER: 201079632
MAIL ADDRESS:
STREET 1: 5 WEST FORSYTH STREET
STREET 2: SUITE 200
CITY: JACKSONVILLE
STATE: FL
ZIP: 32202
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Allovir, Inc.
CENTRAL INDEX KEY: 0001754068
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 831971007
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 139 MAIN STREET, SUITE 500
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (617) 433-2605
MAIL ADDRESS:
STREET 1: 139 MAIN STREET, SUITE 500
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: ViraCyte, Inc.
DATE OF NAME CHANGE: 20180924
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-08-03
0
0001754068
Allovir, Inc.
ALVR
0001763026
Leen Ann M.
C/O ALLOVIR, INC.
139 MAIN STREET, SUITE 500
CAMBRIDGE
MA
02142
0
1
0
0
Chief Scientific Officer
Common Stock
2020-08-03
4
C
0
2436773
A
2436773
I
See Footnote
Common Stock
60394
D
Series A-3 Convertible Preferred Stock
2020-08-03
4
C
0
3631293
D
Common Stock
2436773
0
I
See Footnote
Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date.
Shares held by Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
/s/ Brett Hagen, as Attorney-in-Fact
2020-08-05